Tuesday, September 07, 2010
|
home MEMBERSHIP Membership Benefits Membership Types Join Now Our Members Events Fairs Doing Business Tourism & Studying Careers Links |
Event Detail
| Date | Thursday 22 October 2009 |
| From 16h00 till 17h30 | |
| Event Type | Plant Visit |
| Organised by | BLBG |
| Topic | Plant Visit: GlaxoSmithKline Biologicals Singapore |
| Location | GlaxoSmithKline Biologicals, 10 Tuas South Avenue 8, Singapore 637421 |
| Invite | Official Invitation |
| Description | Opened on 9 June 2009, GlaxoSmithKline Biologicals Singapore is GlaxoSmithKline’s (GSK) first primary vaccine manufacturing facility and its biggest investment in Asia. The plant costs a total investment of S$600 million, and underscores GSK's strong commitment to Singapore and the Asia Pacific region. Built on an 85,000 square metre plot of land, the new state-of-the-art facility will include high-tech production buildings, quality control laboratories, a utility plant, a warehouse and other support buildings. Once operational, the new plant will focus on producing purified bulk polysaccharides and conjugates which are used to manufacture GSK's new pneumococcal conjugate vaccine, meningitis, and other new innovative vaccines. The plant is one of the only two global sites for the production of bulk polysaccharides and conjugates; the other is in Belgium. The first potential commercial lots will be produced in 2011. Part 1 – Presentation by Vincent Hingot, Site Director and David Callaert, Regional Engineering Director of GlaxoSmithKline Biologicals Singapore You are invited to a brief introduction to the facility and its operations. There will be opportunities to share experiences and challenges encountered in setting up this Greenfield site. Part 2 – Site Tour You are invited on a site tour showcasing part of the critical production facilities as well as an array of new cutting-edge technologies employed at GlaxoSmithKline Biologicals Singapore. |
back to the event overview